Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Invested Capital (2023 - 2025)

Monte Rosa Therapeutics' Return on Invested Capital history spans 3 years, with the latest figure at 0.22% for Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 14.0% year-over-year to 0.22%; the TTM value through Dec 2025 reached 0.22%, down 14.0%, while the annual FY2025 figure was 0.23%, 15.0% down from the prior year.
  • Return on Invested Capital reached 0.22% in Q4 2025 per GLUE's latest filing, down from 0.29% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.29% in Q3 2025 to a low of 0.87% in Q1 2024.
  • Average Return on Invested Capital over 3 years is 0.28%, with a median of 0.22% recorded in 2025.
  • The largest YoY upside for Return on Invested Capital was 111bps in 2025 against a maximum downside of -14bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.79% in 2023, then surged by 90bps to 0.08% in 2024, then crashed by -185bps to 0.22% in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Return on Invested Capital are 0.22% (Q4 2025), 0.29% (Q3 2025), and 0.28% (Q2 2025).